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Abstract
This study analyzed a heterologous prime-boost vaccine approach against HIV-1 using three different antigenically
unrelated negative-stranded viruses (NSV) expressing HIV-1 Gag as vaccine vectors: rabies virus (RABV), vesicular stomatitis
virus (VSV) and Newcastle disease virus (NDV). We hypothesized that this approach would result in more robust cellular
immune responses than those achieved with the use of any of the vaccines alone in a homologous prime-boost regimen. To
this end, we primed BALB/c mice with each of the NSV-based vectors. Primed mice were rested for thirty-five days after
which we administered a second immunization with the same or heterologous NSV-Gag viruses. The magnitude and quality
of the Gag-specific CD8+ T cells in response to these vectors post boost were measured. In addition, we performed
challenge experiments using vaccinia virus expressing HIV-1 Gag (VV-Gag) thirty-three days after the boost inoculation. Our
results showed that the choice of the vaccine used for priming was important for the detected Gag-specific CD8+ T cell
recall responses post boost and that NDV-Gag appeared to result in a more robust recall of CD8+ T cell responses
independent of the prime vaccine used. However, the different prime-boost strategies were not distinct for the parameters
studied in the challenge experiments using VV-Gag but did indicate some benefits compared to single immunizations.
Taken together, our data show that NSV vectors can individually stimulate HIV-Gag specific CD8+ T cells that are effectively
recalled by other NSV vectors in a heterologous prime-boost approach. These results provide evidence that RABV, VSV and
NDV can be used in combination to develop vaccines needing prime-boost regimens to stimulate effective immune
responses.
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Introduction
Every year, 50,000 people in the United States become infected
with HIV-1 [1] and one in every 20 adults live with HIV in Sub-
Saharan Africa (UNAIDS report 2012). Despite increasing
knowledge of HIV as a pathogen and the interaction with the
immune system [2], the conundrum is creating a vaccine against a
pathogen for which no adult human has been reported to have
completely cleared an infection [3,4]. The consensus is that the
search for the most effective vaccine is no easy feat partly because
the correlates of complete protection are unclear. However, like
other clinically significant infectious diseases such as smallpox [5],
the need for a vaccine against HIV is of utmost importance in the
management of the global HIV epidemic.
Theoretically, a vaccine strategy most likely to stimulate an
effective response against HIV would be one that can i) efficiently
deliver the antigen to the host, ii) stimulate a robust humoral and
cellular immune response capable of targeting the virus and virus
infected cells, and iii) establish a population of memory cells that
can quickly and efficiently replicate and protect a host exposed to
the actual infection [6].
There has been extensive work done on vaccine development
against HIV in mice and non-human primates (NHPs). Unlike
other pathogens, attenuated HIV as a vaccine has not been
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explored, because attempts to attenuate SIV did not prevent
rhesus macaques from getting an AIDS related illness [7].
Resultingly, other modes of antigen delivery have been explored.
Live attenuated viral vectors have been particularly successful in
the delivery of foreign antigens to the host. Distinct from other
modes of vaccines such as subunit vaccines or DNA-plasmids,
attenuated live viral vectors are able to induce robust cellular and
humoral responses, largely due to their ability to undergo several
rounds of replication in vivo [8]. To date, a number of different
viral vectors have been extensively characterized and studied. A
significant vaccine trial using human adenovirus-5 failed to result
in protection of high-risk individuals from HIV infection [9]. One
of the major drawbacks of this system was thought to be the
presence of pre-existing antibodies against the viral vector [10],
necessitating the characterization of viral vectors with potential for
use in HIV vaccine development. The goal of the project
presented here was to evaluate three well-characterized NSV
vectors in heterologous and homologous prime/boost experi-
ments. The study of multiple vectors in the same laboratory
environment also allows for comparisons to be made between
vectors while keeping other variables static.
Negative-stranded viruses (NSV) comprise four families:
Rhabdoviridae, which includes vesicular stomatitis virus (VSV)
and rabies virus (RABV); Paramyxoviridae, including Newcastle
disease virus (NDV), human parainfluenza virus types, Sendai
virus, mumps virus and measles virus, human respiratory
syncytial and metapneumoviruses; Filoviridae including Ebola
virus and Marburg virus; and Borna disease virus in the
Bornaviridae family. NSVs have an advantage as vaccine vectors
because they replicate in the cytoplasm and therefore do not
have the risk of genetic recombination with host cell DNA. Of
the aforementioned viruses, RABV, VSV and NDV are well-
established candidates for HIV vaccine development. Schnell
et al. first established a reverse genetic system in 1994 that
allowed the recovery of infectious RABV from cloned cDNA
[11]. This system was used to obtain other recombinant NSV
including VSV [12] and NDV [13]. The genomes of these
viruses can be readily manipulated to express multiple foreign
genes [14,15]. Unlike adenovirus-5, most individuals have not
been previously exposed to these viruses and are thus
seronegative. This factor makes them rank highly as potential
viral vaccine candidates. In addition, all these viruses have been
extensively studied as potential HIV/SIV vaccine vectors and
shown to induce potent immune responses [15–19].
RABV and VSV are single-stranded negative sense RNA
viruses of the family Rhabdoviridae. They have simple genomes that
encode 5 genes – nucleoprotein (N), phosphoprotein (P), matrix
protein (M), glycoprotein (G) and the large protein (L). The SAD
B19 strain of RABV is an attenuated strain used for vaccine
development that has been shown to be safe in mice [15,16,20–27]
and NHPs [24,26], without any vector-induced pathogenicity.
RABV vaccine vectors engineered to express HIV-1 envelope and
structural proteins gp160, Gag and Pol are immunogenic in mice
and NHPs [15,16,20–28]. Of note, NHPs immunized with RABV
expressing SIVmac239 Gag-Pol and SIVmac239 Env were protected
from AIDS-like illness when challenged with the highly pathogenic
SIV mac251 strain compared to controls [26].
Because of its neurovirulence in animal models, VSV vaccine
vectors have been attenuated to make them safe vaccine vectors
using several different approaches [17]. The vectors used here are
based on M protein mutants of VSV [29–31]. Wild-type VSV-M
protein is known to suppress host expression of genes needed in the
innate responses (reviewed in [32]). Single-amino acid substitu-
tions such as the M51R substitution in M protein have resulted in
vectors that activate rather than suppress innate responses
[29,33,34]. These vectors are as immunogenic as wild-type VSV
but lack neurovirulence, which also improves their safety profile
[30,31].
NDV is an avian paramyxovirus that naturally infects different
avian species. NDV strains are classified into three categories
according to their virulence in poultry, velogenic, mesogenic and
lentogenic. Lentogenic strains do not cause disease in poultry and
have been widely used as live poultry vaccines against virulent
(velogenic) strains of NDV. NDV undergoes only limited rounds of
replication in mammals due to its inability to inhibit innate
immune responses in these hosts [35]. Lentogenic strains of NDV
expressing foreign antigens have been demonstrated to be
immunogenic in multiple animals, including mice [13], chicken
[36,37], sheep [38] cattle [39], and NHP [40].
In this study, we explored the utility of RABV, VSV and NDV
as vaccine vectors against HIV-1 Gag in a heterologous prime-
boost regimen. HIV-1 Gag specific CD8+ T cell induction was
analyzed in different prime-boost regimens. We found that all
three NSVs were capable of boosting the immune responses of one
another. NDV-Gag and VSV-Gag induced significantly higher
responses than RABV when used as boost vaccines. There were no
notable differences post-challenge with VV-Gag. In general, all
three NSVs were compatible as prime-boost vaccines.
Materials and Methods
Mice
Six to eight week old female BALB/c mice (NIH) were
maintained at the Thomas Jefferson University Animal Facili-
ties. All animals were handled in strict accordance with good
animal practice as defined by the relevant international
(Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC) (Accreditation Status TJU: Full)) and
national regulations (TJU Animal Welfare Assurance Number:
A3085-01), and all animal work was approved by the
Institutional Animal Care and Use Committee (IACUC) at
Thomas Jefferson University TJU. Animal use protocols are
written and approved in accordance with Public Health Service
Policy on Humane Care and Use of Laboratory Animals, The
Guide for the Care and Use of Laboratory Animals. TJU
IACUC protocol number 414 A.
Recombinant Vaccine Vectors
The vaccine vectors (Figure 1A) in this study have been
previously characterized. RABV-Gag has been previously pub-
lished as BNSP-Gag [15]. We constructed a RABV-vaccine vector
expressing optimized HIV-1 Gag (Optgag) using cDNA published
[18], but characterization of this vector revealed lower levels of
expression of Gag in the cells and supernatants of infected cells
compared to RABV-Gag (data not shown). SPBN-Ig-Gag is the
RABV vector in which the RABV glycoprotein gene was
exchanged with the ectodomain and transmembrane domain of
VSV Indiana strain fused to the cytoplasmic domain of RABV-G
[41,42]. In this paper it is cited as RABV-Ig-Gag.
VSV-Gag was generated from the VSV-M51R, which is
attenuated due to the mutation in the matrix protein [29–31].
The HIV-1 Gag in the VSV-Gag vector is codon optimized Gag.
The codon-optimized Gag gene [18] was amplified by PCR using
the primers 59GGGGTTAATTAAGCCACCATGGGCGT-
GAG-39 and 59-GGGGTTAATTAACTACTGGTCTC-39. The
PCR product was cleaved with Pac I and cloned into the Pac I site
of the M protein mutant VSV B5R cDNA infectious clone
described in [31]. Infectious virus was recovered from plasmid
Heterologous Prime-Boost against HIV-1 Using NSV
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DNA, and virus stocks were prepared as described [43]. The
correct orientation and sequence of the insert was confirmed by
sequencing the plasmid DNA and cDNA prepared by RT-PCR of
the genome of the recovered virus. Characterization of this vaccine
construct by western blot analysis showed increased expression
levels of Gag in cells infected with the vector and in the
supernatant (data not shown). As such this was used in our studies.
The NDV vector expressing codon-optimized Gag gene has
been previously characterized and published [18] and is designat-
ed as NDV-Gag in this paper.
Quantification of HIV-1 Gag – p24 ELISA
VERO cells were seeded in a 12-well plate (26105 cells per well)
the day before infection. The following day they were infected at a
multiplicity of infection (MOI) of five with BNSP-gag, VSV-
optGag, and NDV-optGag in 250 ml serum-free Optimem
medium. After 1 h at 37uC the inoculum was removed and
replaced with 1 ml fresh Optimem medium and incubation was
continued at 37uC. Supernatant was collected at the times
indicated in the figure, spun at 10.000 rpm for 3 min and
transferred to a fresh tube. Cells were washed once with 1 ml PBS
and then resuspended in lysis buffer [40 mM HEPES pH 7.5,
120 mM NaCl, 1% Triton-X100, 0.4% NaDOC, 1 mM EDTA]
supplemented with 1% HALT protease inhibitor cocktail
(ThermoScientific Inc.). Lysate was centrifuged for 10 min at
14.000 rpm and transferred to fresh tubes. Protein concentration
in the lysate was measured with a BCA kit (Thermofisher) and
adjusted to 0.1 mg/ml by the addition of lysis buffer. Supernatant
and lysate were diluted with Optimem and PBS, respectively, and
assayed for p24 with a RETROTEK HIV-1 p24 Antigen ELISA
kit according to the manufacturers instructions (ZeptroMetrix,
Buffalo NY).
Immunization and Challenge Protocol
Mice were primed intramuscularly (i.m.) with either 16106 foci
forming units (ffu) of RABV-Gag (Day 0), 16106 ffu VSV-Gag
(Day 0), or 56106 ffu NDV-Gag (on Day 0 and 6) in 100 mL
administered as two injections –50 mL per hind limb.
For the boost experiments, the mice were rested for 35 days
after the prime and then boosted i.m. with either 16106 ffu
RABV-IG-Gag, 16106 ffu VSV-Gag, 56106 ffu NDV-Gag (on
Day 29 and 35), or did not receive a boost as a control (n = 5 per
group). PBS only mice were included as a negative control. Mice
were euthanized 5 days after boost, and spleens were harvested for
analysis of the cellular response.
For the challenge experiments, the mice were rested for 33 days
after the boost and then challenged intraperitoneally (i.p.) with
16106 plaque forming units (pfu) of recombinant vaccinia virus
expressing HIV-1 Gag (vP1287, ARRRP – cited as VV-Gag) in
300 mL (n = 5 per group). Mice receiving PBS only were included
as a negative control. Mice were euthanized 5 days after
challenge, and spleens were harvested for analysis of the recall
response.
FACS Analysis
Cells were stained for flow cytometry as previously described
[44]. In brief, the spleen from the mouse was homogenized and a
single-cell suspension of splenocytes obtained. The cells were
blocked for 1 hour at 4uC in 100 ml FACS buffer (2% Bovine
Serum Albumin in PBS) containing 2 ml Fc block (anti-CD16/32,
BD Biosciences) and 3.3 ml unconjugated streptavidin per 16106
cells in order to reduce non-specific binding by the streptavidin-
conjugated tetramer antibody. The cells were washed twice in
FACS buffer and then stained for 30 minutes at room temperature
with fluorochrome-linked antibodies against cell surface antigens:
Figure 1. Recombinant vectors and p24 expression levels. (A) The genomes of different recombinant vectors expressing HIV-1 Gag protein
used throughout this study are illustrated. The representation of the different genes is not to scale. F, fusion protein; G, glycoprotein; HN,
haemagglutinin-neuraminidase protein; L, polymerase; M, matrix protein; N, nucleoprotein; NP, nucleocapsid protein; P, phosphoprotein; P/V,
phosphoprotein. (B–C) For quantification of HIV-1 Gag expression levels by p24 ELISA, VERO cells were infected at a MOI of 5 with RABV-Gag, VSV-
Gag, and NDV-Gag. Cell lysates (B) and supernatant (C) were collected at the times indicated and p24 antigen levels were measured by ELISA.
doi:10.1371/journal.pone.0067123.g001
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PerCP-CD8a (BD Biosciences), APC-CD62L (BD Biosciences),
and PE-AMQMLKETI tetramer (Becton Dickinson). After
surface staining, cells were washed and fixed with 4% parafor-
maldehyde (BD-cytofix buffer, BD Biosciences) for 20 minutes at
4uC. Cells were washed and re-suspended in FACS buffer and
analyzed on an LSRII machine (BD) at the Kimmel Cancer
Center Cytometry Facility (Thomas Jefferson University); 200,000
events were collected from each immunized mouse. When
analyzing flow cytometry data from splenocytes, the cells were
first gated on viability (using forward and side scatter) and then
gated for CD8a. All FACS data were analyzed using FlowJo
(version 9.5.3) software.
Intracellular Staining
For the functional analysis of T cells, 16106 splenocytes/ml
were plated in 96-well plate in the presence of GolgiPlug (BD
Biosciences) and GolgiStop (BD Biosciences) followed by an
incubation for 6 hours at 34uC and 5% CO2. For each mouse, two
groups were analyzed; the antigen-stimulated group pulsed with
10ug/mL AMQMLKETI peptide and the non-stimulated group
left without peptide. The cells were incubated with fluorochrome-
linked antibodies against surface proteins - PerCP-CD8a (BD
Biosciences) - for 30 minutes at room temperature. Cells were
washed and fixed with 4% paraformaldehyde (BD-cytofix buffer,
BD Biosciences) for 20 minutes at 4uC, after which cells were
washed in Perm/Wash Buffer (BD Bioscience). Cells were then
stained for 30 minutes at room temperature in Perm/Wash Buffer
containing antibodies against internal antigens: APC-TNFa (BD
Pharmingen) and PE-IFNc (Becton Dickinson). Cells were re-
suspended in FACS buffer and FACS analysis was performed as
described above.
Statistical Analysis
All data were analyzed by Prism software (GraphPad, version
5.0d). Statistical analysis was performed using unpaired t-test to
compare two groups and represented as two-tailed p-value with a
confidence interval of 95%. One-way ANOVA with Bonferroni
post-test analysis was used where more than two groups were
compared. Presented results show the mean of measurements
within a group. For all statistics, the following notations are used to
indicate significance between two groups: *p,0.05, **p,0.01,
***p,0.001, ****p,0.0001.
Results
Utilized Vaccine Vectors Expressing HIV-1 Gag
The vaccine vectors for this heterologous prime/boost approach
were RABV-Gag, RABV-IG-Gag (which expresses VSV-Indiana
G instead of RABV G), VSV-Gag, or NDV-Gag (Figure 1A). To
analyze Gag expression levels for the three vaccine vectors, VERO
cells were infected at a MOI of 5 with BNSP-Gag, VSV-Gag, and
NDV-Gag. Cell lysates (Figure 1B) and supernatants (Figure 1C)
were then collected and at the times indicated p24 antigen was
measured by ELISA. Our results indicate that VSV-Gag did
express the highest amount of HIV-1 Gag whereas NDV
expressed the lowest level of Gag as detected by p24 ELISA.
Surprisingly RABV expressed more p24 than detected for NDV-
Gag even though the RABV-based vector does not contain the
codon-optimized Gag utilized for the other two vectors.
Boost with NDV-Gag in Mice Primed with RABV-Gag and
VSV-Gag
CD8+ T cells are important effector cells in the control of HIV
along with the humoral response against this virus, which is not
studied here [45,46]. Induction of an effective T cell response
requires replication of the vectors to achieve adequate antigen
expression levels in both the priming and boosting phases. As such
heterologous vaccine regimens might facilitate sufficient replica-
tion of the vectors to enhance the resulting cellular immune
response, since they avoid the problem of anti-vector immunity in
the boosting phase that is typical of homologous prime/boost
protocols. To analyze the benefits of a heterologous prime/boost
approach, we immunized mice with RABV-Gag followed by a
second immunization with RABV-IG-Gag (which expresses VSV-
Indiana G instead of RABV G), VSV-Gag, or NDV-Gag
(Figure 2A). Of note, throughout this study NDV-Gag was always
applied twice 6 days apart, because the initial NDV infection does
not prevent a second immunization by vector-specific antibodies as
observed for RABV and VSV [13]. Two additional groups of mice
did not receive any boost or were given an equal volume of PBS as
a control. Following the boost immunization, the percentage of
HIV-1 Gag specific cells was measured by AMQMLKETI
tetramer on activated CD62Llo CD8+ T cells (Figure 2B).
Functional expression of cytokines by CD8+ T cells was analyzed
by intracellular cytokine staining (Figure 2C–E). As shown in
Figure 2, mice immunized with NDV-Gag had significantly higher
induction of Gag-specific CD8+ cells compared to VSV-Gag
(p,0.0001) and RABV-IG-Gag (p,0.01). Similarly, a higher
percentage of activated CD8+ T cells from mice boosted with
NDV-Gag expressed IFN-c (p,0.0001), TNF-a (p,0.05), or both
IFN-c and TNF-a (p,0.001).
Similar trends were seen in mice primed with VSV-Gag
followed by boosting with RABV-Gag or NDV-Gag (Figure 3A).
NDV-Gag induced more robust CD8+ T cell responses compared
to all other groups (p,0.001) (Figure 3B). Expression of
inflammatory cytokines was similar to the level of activation
(IFN-c (p,0.0001), TNF-a (p,0.0001), IFN-c and TNF-a
(p,0.001–0.0001)) (Figure 3C).
CD8+ T Cell Responses in Mice Primed with NDV-Gag
Mice were primed with NDV-Gag followed by heterologous
immunizations with VSV-Gag or RABV-Gag as shown
(Figure 4A). Both regimens increased the CD8+ T cell response
to NDV-Gag compared to the controls (Figure 4B). VSV-Gag
induced significantly more HIV-1 Gag specific CD8+ T cells than
RABV-Gag (p,0.05). A similar trend was seen with expression of
IFN-c (p,0.0001), TNF- a (p,0.05), and IFN-cTNF-a
(p,0.0001) (Figure 4C–E). Not surprisingly, homologous respons-
es with NDV-Gag were lower than RABV-Gag or VSV-Gag. Of
note, IFN-c and TNF-a expression in mice that were primed and
boosted with NDV-Gag were lower than mice that were not
boosted (Figure 4C, D). Taken together, VSV-Gag effectively
increased the CD8+ T cell response after NDV-Gag prime,
whereas this increase was not seen at a similar level after the boost
with the RABV-based vaccine vector.
CD8+ T Cell Responses in Vaccine Groups after Challenge
with a Recombinant Vaccinia Virus Expressing HIV-1 Gag
While the boost responses the boost responses after immuniza-
tion with a heterologous vaccine vector might predict the
efficiency of the approach, the final goal of a vaccine is the
induction of long-term memory cells, which will control future
infection through a recall response. Therefore, mice primed with
RABV-Gag followed by heterologous immunizations with the
other vectors were challenged with VV-Gag as shown (Figure 5A).
The percentage of HIV-1 Gag CD8+ T cells (Figure 5B), as well as
the expression of IFN-c and TNF-a, was analyzed as above
(Figure 5C–E). Of note, although NDV-Gag induced the most
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robust CD8+ T cell response when used to boost mice immunized
with the other NSVs, mice that had been boosted with NDV-Gag
had a lower recall response after VV-Gag challenge. Differences
between NDV-Gag and VSV-Gag in IFN-c+ cells were statistically
significant (p,0.001). In the second series of challenge experi-
ments, mice that were primed with VSV-Gag followed by booster
immunization with the other NSVs were challenged with VV-Gag
(Figure 6). In general, challenge with VV-Gag resulted in strong
responses in all groups compared to the PBS only group, which did
not induce any HIV-1 Gag-specific cells. Subtle differences in
percentage of IFN-c+ (p,0.0001) and TNF-a+ (p,0.05) cells were
evident when comparing boosted group responses to those from
animals that received VSV-Gag prime only.
The third experimental group of NDV-primed animals were
heterologously boosted and then challenged with VV-Gag as
described (Figure 7A). Animals boosted with RABV-Gag or VSV-
Gag generated significantly higher percentages of TNF- a+cells
(p,0.05) compared to mice that were not boosted. Similarly,
VSV-Gag induced higher expression of TNF-a than unboosted
mice (p,0.01). Cells that co-express IFN-c and TNF-a were
higher in both RABV-Gag and VSV-Gag boosted animals
compared to unboosted (p,0.05).
Comparison of Challenge Responses Across All Groups
A comparison of the post-challenge cellular immune responses
of all the groups included in this study was performed to identify
combinations that induced robust immune responses. Overall
Figure 2. Analysis of Gag-specific CD8+ T Cells in the spleen after RABV-Gag prime and heterologous boost. (A) Schedule of prime-
boost vaccinations. Mice were primed intramuscularly. Mice mock-immunized with PBS were included as a negative control. (B–D) Each point is
representative of splenocytes from one mouse (n = 5 per group). (B) The quantity of activated HIV-1 Gag-specific CD8+ T cells in the spleen was
analyzed by flow cytometry and the percentage of cells are shown. Activated cells were determined by gating on CD62Llo cells and HIV-1 Gag-
specific cells were determined by tetramer staining against the H2d restricted AMQMKLETI epitope. (C–E) The functionality of the CD8+ T cells was
measured by intracellular cytokine staining for (C) IFNc+, (D) TNFa+, and (E) IFNc+TNFa+ cells after stimulation of the cells with AMQMKLETI peptide.
Statistical analysis was performed using One-WayANOVA. Results shown are presented as the mean. *p,0.05, **p,0.01, ***p,0.001, ****p,0.0001.
doi:10.1371/journal.pone.0067123.g002
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VSV-Gag prime induced HIV-1 Gag specific immune responses
that were higher than responses in mice primed with RABV-Gag
and NDV-Gag (Figure S1A–D). Within the VSV-Gag prime
group, boosting twice with NDV-Gag induced the highest
amounts of Gag-specific CD8+ T cells.
Discussion
Like many infectious diseases that have had significant impact
on the human population, a vaccine against HIV is critically
needed. Along with humoral immunity, CD8+ T cells have been
shown to be important in the control of HIV [45,46]. Cellular
immunity induced in the Ad5-STEP trial failed to protect
individuals from HIV, resulting in more people from the
vaccine group acquiring infection compared to the placebo [47].
Part of the problem was thought to be the presence of pre-
existing immunity against the vector [47,48]. The NSVs used in
this study were chosen, because few individuals have pre-
existing immunity.
RABV, VSV and NDV as vaccine vectors against HIV-1 Gag
have been extensively studied [15–18]. Their genomes are easy to
manipulate for insertion of multiple genes without affecting
replication [11–15]. Furthermore, their pathogenicity and immu-
Figure 3. Analysis of the Gag-specific CD8+ T Cells in the spleen after VSV-Gag prime and heterologous boost. (A) Schedule of prime-
boost vaccinations. Mice were primed intramuscularly. 35 days later the mice were boosted. Mice mock-immunized with PBS were included as a
negative control. 5 days after boost, mice were euthanized and spleens harvested for analysis of the cellular response. (B–D) Each point is
representative of splenocytes from one mouse (n = 5 per group). (B) The quantity of activated HIV-1 Gag-specific CD8+ T cells in the spleen was
analyzed by flow cytometry and the percentage of cells are shown. Activated cells were determined by gating on CD62Llo cells and HIV-1 Gag-
specific cells were determined by tetramer staining against the H2d restricted AMQMKLETI epitope. (C–E) The functionality of the CD8+ T cells was
measured by intracellular cytokine staining for (C) IFNc+, (D) TNFa+, and (E) IFNc+TNFa+ cells after stimulation of the cells with AMQMKLETI peptide.
Statistical analysis was performed using One-WayANOVA. Results shown are presented as the mean. *p,0.05, **p,0.01, ***p,0.001, ****p,0.0001.
doi:10.1371/journal.pone.0067123.g003
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nogenicity have extensively been studied in mice and NHP
[13,17,18,20,21,24,26,30,31,38,40], and appropriately attenuated
vectors have been developed. In this study, we analyzed HIV-
1 Gag CD8+ T cell responses using each combination of the NSV
vectors. Heterologous combinations of the vectors were able to
boost HIV-1 Gag CD8+ T cells compared to not boosted control
animals (Figures 2, 3, 4). As expected, homologous combinations
were not as effective at improving the response due to pre-existing
immunity to the vector for RABV and VSV. NDV-Gag induced
significantly higher CD8+ target cell responses in mice primed with
RABV-Gag (Figure 2) and VSV-Gag (Figure 3); however, we need
to consider that, in the case of NDV-Gag, two boost immuniza-
tions were applied. As in previous studies, RABV-IG-Gag was also
able to boost responses to RABV-Gag, because it contains the
ectodomain and transmembrane domain of the VSV-G Indiana
strain [26]. On the other hand, VSV-Gag induced the higher
CD8+ T cell response in mice primed with NDV-Gag. Together,
these post-boost data imply that both NDV-Gag and VSV-Gag
are good candidates for use as boost vaccines with any of the three
NSVs analyzed in this study. One interesting result of this study
was that NDV-Gag was able to efficiently boost Gag-specific
CD8+ cells after RABV-Gag priming, but VSV-Gag failed to do so
(Figure 2B). This finding might help to further elucidate the
mechanism of secondary responses for HIV-1 vaccines, and we do
Figure 4. Analysis of the Gag-specific CD8+ T Cells in the spleen after NDV-Gag prime and heterologous boost. (A) Schedule of prime-
boost vaccinations. Mice were primed intramuscularly on Day 0 and 6. 35 days later the mice were boosted. Mice mock-immunized with PBS were
included as a negative control. 5 days after boost, mice were euthanized and spleens harvested for analysis of the cellular response. (B–D) Each point
is representative of splenocytes from one mouse (n = 5 per group). (B) The quantity of activated HIV-1 Gag-specific CD8+ T cells in the spleen was
analyzed by flow cytometry and the percentage of cells are shown. Activated cells were determined by gating on CD62Llo cells and HIV-1 Gag-
specific cells were determined by tetramer staining against the H2d restricted AMQMKLETI epitope. (C–E) The functionality of the CD8+ T cells was
measured by intracellular cytokine staining for (C) IFNc+, (D) TNFa+, and (E) IFNc+TNFa+ cells after stimulation of the cells with AMQMKLETI peptide.
Statistical analysis was performed using One-WayANOVA. Results shown are presented as the mean. *p,0.05, **p,0.01, ***p,0.001, ****p,0.0001.
doi:10.1371/journal.pone.0067123.g004
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suspect that differences in the pattern of cytokine induction pattern
might be responsible for the observed effects [26].
It is important to note that the codon-optimized Gag gene
inserts were cloned into the VSV and NDV recombinant vectors.
Studies with NDV expressing codon-optimized Gag have been
published [49]. Optimized Gag expression did not alter NDV
recovery, which grew to similar levels as NDV control vectors.
Furthermore, increased Gag expression enhanced the CD8+ T cell
response as determined by reduction in VV-Gag titers in challenge
experiments. Similarly, higher levels of HIV-1 Gag were expressed
by VSV with optimized HIV-1 Gag than by VSV with non-
optimized HIV-1 Gag (data not shown). RABV expressing codon
optimized Gag on the other hand did not express higher levels of
Gag in the cell lysate or supernatant. In fact, the expression levels
of Gag and RABV-N were lower when using codon-optimized
Gag compared to the wild-type vector. One possible explanation is
that codon optimization leads to differences in viral replication
and transcription in the case of RABV. However, Gag expression
levels cannot explain the robust post boost responses by VSV-Gag
and NDV-Gag (Figure 1B and C), because NDV did express the
Figure 5. Recall response in mice after RABV-Gag prime and heterologous boost. (A) Schedule of prime-boost-challenge vaccinations. Mice
were primed intramuscularly. 35 days later the mice were boosted. Mice were challenged intraperitoneally 33 days post prime. PBS mice were
included as a negative control. 5 days after challenge, mice were euthanized and spleens harvested for analysis of the cellular response. (B–D) Each
point is representative of splenocytes from one mouse (n = 5 per group). (B) The quantity of activated HIV-1 Gag-specific CD8+ T cells in the spleen
was analyzed by flow cytometry and the percentage of cells are shown. Activated cells were determined by gating on CD62Llo cells and HIV-1 Gag-
specific cells were determined by tetramer staining against the H2d restricted AMQMKLETI epitope. (C–E) The functionality of the CD8+ T cells was
measured by intracellular cytokine staining for (C) IFNc+, (D) TNFa+, and (E) IFNc+TNFa+ cells after stimulation of the cells with AMQMKLETI peptide.
Statistical analysis was performed using One-Way ANOVA. All comparisons to PBS are statistically significant. Results shown are presented as the
mean. **p,0.05, **p,0.01, ***p,0.001, ****p,0.0001.
doi:10.1371/journal.pone.0067123.g005
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least amount of HIV Gag while VSV expressed the highest
amount of Gag. Of note, both NDV and VSV are potent inducers
of type I IFN responses, which might support effective boosting.
The challenge studies in the mice were done using VV-Gag as
previously published [50,51]. VV-Gag is a virus that replicates and
induces robust responses against foreign antigens like HIV-1 Gag
in mice. The results from the challenge experiment showed that all
prime-boost regimens generated significant recall responses
compared to naı¨ve controls (Figures 5, 6, 7). Post VV-Gag
challenge, mice that had been boosted with NDV-Gag had a lower
CD8+ T cell response as compared to RABV-Gag and VSV-Gag
boosted mice. This is not what we would have expected based on
the robust responses induced by NDV-Gag boost data (Figure 2–
3). One difference between the boost and challenge studies was the
immunization schedule: 35 days between prime and boost
compared to 33 days between prime and challenge. However,
previous studies have shown good challenge responses at 3 weeks
post boost with NDV-Gag [18]. This could potentially be due to
differences in long-term memory CD8+ T cells.
Figure 6. Recall response in mice after a VSV-Gag prime and heterologous boost. (A) Schedule of prime-boost-challenge vaccinations.
Mice were primed intramuscularly. 35 days later the mice were boosted. Mice were challenged intraperitoneally 33 days post prime. PBS mice were
included as a negative control. 5 days after challenge, mice were euthanized and spleens harvested for analysis of the cellular response. (B–D) Each
point is representative of splenocytes from one mouse (n = 5 per group). (B) The quantity of activated HIV-1 Gag-specific CD8+ T cells in the spleen
was analyzed by flow cytometry and the percentage of cells are shown. Activated cells were determined by gating on CD62Llo cells and HIV-1 Gag-
specific cells were determined by tetramer staining against the H2d restricted AMQMKLETI epitope. (C–E) The functionality of the CD8+ T cells was
measured by intracellular cytokine staining for (C) IFNc+, (D) TNFa+, and (E) IFNc+TNFa+ cells after stimulation of the cells with AMQMKLETI peptide.
Statistical analysis was performed using one-WAY ANOVA. All comparisons to PBS are statistically significant. Results shown are presented as the
mean. *p,0.05, **p,0.01, ***p,0.001, ****p,0.0001.
doi:10.1371/journal.pone.0067123.g006
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The functional profile of the cells induced in the immune
responses was determined by analyzing expression of IFN-c and
TNF-a. Other cytokines analyzed included IL-2, IL-6 and IL-10.
However, the levels of expression of these latter cytokines
compared to background were too low and therefore not included
(data not shown). In general, expression and co-expression of IFN-
c and TNF-a was proportional to the magnitude of the immune
response induced post boost (Figure 2, 3, 4) and post challenge
(Figure 5, 6, 7 and Figure S1).
The potential of these vectors as vaccine against HIV-1 Gag has
previously been established [15–18,52].
In this study, we show that RABV, VSV and NDV are
compatible in a heterologous prime-boost regimen. They are all
able to enhance immune responses primed by each other, and they
all induced long-term memory cells that could be recalled during
challenge. NDV-Gag and VSV-Gag elicited the strongest post
boost immune responses likely due to induction of type I interferon
responses while VSV-Gag primed mice in general appeared to
have the highest responses post challenge. Now that we have
Figure 7. Recall response in mice after NDV-Gag prime and heterologous boost. (A) Schedule of prime-boost-challenge vaccinations. Mice
were primed intramuscularly on Day 0 and 6. 35 days later the mice were boosted. Mice were challenged intraperitoneally 33 days post prime. PBS
mice were included as a negative control. 5 days after challenge, mice were euthanized and spleens harvested for analysis of the cellular response.
(B–D) Each point is representative of splenocytes from one mouse (n = 5 per group). (B) The quantity of activated HIV-1 Gag-specific CD8+ T cells in
the spleen was analyzed by flow cytometry and the percentage of cells are shown. Activated cells were determined by gating on CD62Llo cells and
HIV-1 Gag-specific cells were determined by tetramer staining against the H2d restricted AMQMKLETI epitope. (C–E) The functionality of the CD8+ T
cells was measured by intracellular cytokine staining for (C) IFNc+, (D) TNFa+, and (E) IFNc+TNFa+ cells after stimulation of the cells with AMQMKLETI
peptide. Statistical analysis was performed using one-WAY ANOVA. All comparisons to PBS are statistically significant. Results shown are presented as
the mean. *p,0.05, **p,0.01, ***p,0.001, ****p,0.0001.
doi:10.1371/journal.pone.0067123.g007
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established their compatibility, a vaccine regimen with RABV-
Gag prime, NDV-Gag Boost #1 and VSV-Gag Boost #2 would
be a great candidate to study in mice and macaques with more
emphasis on the function of the CD8+ T cells. The further
addition of envelope proteins for stimulation of humoral responses
can be explored.
Supporting Information
Figure S1 Comparison of the recall response after the
same boost vaccine. Mice that had been previously immunized
and boosted as indicated were challenged intraperitoneally with
16106 PFU of VV-Gag at 33 days post prime. Five days after
challenge, mice were euthanized, and spleens were harvested for
analysis of the recall response. (A–D) Each point is representative
of splenocytes from one mouse (n = 5 per group). (A) The quantity
of activated HIV-1 Gag-specific CD8+ T cells in the spleen was
analyzed by flow cytometry and the percentage of cells are shown.
Activated cells were determined by gating on CD62Llo cells and
HIV-1 Gag-specific cells were determined by tetramer staining
against the H2d restricted AMQMKLETI epitope. (B–D) The
functionality of the CD8+ T cells was measured by intracellular
cytokine staining for (B) IFNc+, (C) TNFa+, and (D) IFNc+TNFa+
cells after stimulation of the cells with AMQMKLETI peptide.
Statistical analysis was performed using unpaired t-test to compare
two groups. Results shown are presented as the mean. *p,0.05,
**p,0.01, ***p,0.001, ****p,0.0001.
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